Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
Front Endocrinol (Lausanne). 2021 Mar 26;12:624686. doi: 10.3389/fendo.2021.624686. eCollection 2021.
Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use.
高达 35%的侵袭性垂体瘤会复发，并显著影响死亡率和生活质量。其治疗具有挑战性，往往需要多模式治疗。目前的治疗选择，包括手术、多巴胺激动剂、生长抑素受体激动剂和放射治疗等传统药物治疗，往往无法抑制垂体瘤的生长。最近，替莫唑胺、卡培他滨和依维莫司等化疗药物以及肽受体放射性核素治疗对侵袭性垂体瘤的抗肿瘤作用越来越受到关注，结果喜忧参半。本文综述的目的是提供关于侵袭性垂体腺瘤的非手术性药物治疗及其疗效和应用方案的全面信息，从临床前水平到临床应用。
